SEC Comment Letter 0000000000-23-003196 to Krystal Biotech, Inc. (KRYS) (CIK 0001711279) (KRYS)
Krystal Biotech, Inc. (KRYS) (CIK 0001711279)
Date: March 30, 2023 · CIK: 0001711279 · Accession: 0000000000-23-003196
AI Filing Summary & Sentiment
File numbers found in text: 001-38210
Letter
United States securities and exchange commission logo March 30, 2023 Kathryn A. Romano Chief Accounting Officer Krystal Biotech, Inc. 2100 Wharton Street, Suite 701 Pittsburgh, PA 15203 Re:Krystal Biotech, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed Feberuary 27, 2023 File No. 001-38210 Dear Kathryn A. Romano: We have reviewed your filing and have the following comment. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Form 10-K for the Fiscal Year Ended December 31, 2022 Research and Development Expenses, page 60 1.Given the importance of research and development expenses to your business model and the multiple product candidates under development, please revise future filings to disclose total costs by product candidate as well as by the nature of expense for each period presented. To the extent that you do not track expenses by product candidate, please disclose as such.
FirstName LastNameKathryn A. Romano Comapany NameKrystal Biotech, Inc. March 30, 2023 Page 2 FirstName LastName Kathryn A. Romano Krystal Biotech, Inc. March 30, 2023 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Gary Newberry at (202) 551-3761 or Kevin J. Kuhar, Accounting Branch Chief, at (202) 551-3662 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
March 30, 2023
Kathryn A. Romano
Chief Accounting Officer
Krystal Biotech, Inc.
2100 Wharton Street, Suite 701
Pittsburgh, PA 15203
Re:Krystal Biotech, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed Feberuary 27, 2023
File No. 001-38210
Dear Kathryn A. Romano:
We have reviewed your filing and have the following comment. In some of our
comments, we may ask you to provide us with information so we may better understand your
disclosure.
Please respond to this comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this comment, we may have additional comments.
Form 10-K for the Fiscal Year Ended December 31, 2022
Research and Development Expenses, page 60
1.Given the importance of research and development expenses to your business model and
the multiple product candidates under development, please revise future filings to disclose
total costs by product candidate as well as by the nature of expense for each period
presented. To the extent that you do not track expenses by product candidate, please
disclose as such.
FirstName LastNameKathryn A. Romano
Comapany NameKrystal Biotech, Inc.
March 30, 2023 Page 2
FirstName LastName
Kathryn A. Romano
Krystal Biotech, Inc.
March 30, 2023
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Gary Newberry at (202) 551-3761 or Kevin J. Kuhar, Accounting Branch
Chief, at (202) 551-3662 with any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences